Leukocyte immunoglobulin-like receptor B4(LILRB4)in acute myeloid leukemia:From prognostic biomarker to immunotherapeutic target  

作　　者：Muzi Li Xiangyu Zhao 

机构地区：[1]Peking University People’s Hospital,Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,National Clinical Research Center for Hematologic Disease,Beijing 100044,China

出　　处：《Chinese Medical Journal》2024年第22期2697-2711,共15页中华医学杂志(英文版)

基　　金：supported by grants from National Natural Science Foundation of China(Nos.82350105,82270228,and 82070184);Science,Technology&Innovation Project of Xiongan New area(No.2023XACX0004);Beijing Nova Program(No.20220484235);Clinical Medicine Plus X-Young Scholars Project of Peking University,the Fundamental Research Funds for the Central Universities,Peking University People’s Hospital Research and Development Funds(No.RDL2021-01)。

摘　　要：Leukocyte immunoglobulin-like receptor(LILR)B4(also known as ILT3/CD85k)is an immune checkpoint protein that is highly expressed in solid tumors and hematological malignancies and plays a significant role in the pathophysiology of cancer.LILRB4 is highly expressed in acute myeloid leukemia(AML),and this phenotype is associated with adverse patient outcomes.Its differential expression in tumors compared to normal tissues,its presence in tumor stem cells,and its multifaceted roles in tumorigenesis position it as a promising therapeutic target in AML.Currently,several immunotherapies targeting LILRB4 are undergoing clinical trials.This review summarizes advancements made in the study of LILRB4 in AML,focusing on its structure,ligands,expression,and significance in normal tissues and AML;its protumorigenic effects and mechanisms in AML;and the application of LILRB4-targeted therapies in AML.These insights highlight the potential advantages of LILRB4 as an immunotherapeutic target in the context of AML.

关 键 词：LILRB4 Leukemia myeloid acute Immune checkpoint Tumor microenvironment Immunotherapy 

分 类 号：R73[医药卫生—肿瘤]